Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, BS-10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India.
Division of Endocrinology, CSIR-Central Drug Research Institute, BS-10/1, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow 226031, India.
Eur J Med Chem. 2018 Aug 5;156:103-117. doi: 10.1016/j.ejmech.2018.06.062. Epub 2018 Jun 28.
Twenty-four novel benzofuran-pyran derivatives were synthesized and evaluated for their anti-osteoporotic activity in primary cultures of rat calvarial osteoblasts in vitro. Among all the compounds screened for the alkaline phosphatase activity, three compounds 4e, 4j and 4k showed potent activity at picomolar concentrations in osteoblast differentiating stimulation. Additionally, these compounds were found effective in mineralization, assessed by alizarin red-S staining assay. Compounds were again validated through a series of other in vitro experiments. Moreover, molecular dynamics simulations demonstrated that both benzofuran and pyran moieties are requisite to fit into the active site of BMP-2 receptor, a key target of the osteogenic agents. The obtained results strongly convey that compound 4e is a potential bone anabolic agent among synthesized series, which can be further explored as a drug lead for treating osteoporosis.
合成了 24 种新型苯并呋喃-吡喃衍生物,并在体外原代培养的大鼠颅骨成骨细胞中评价它们的抗骨质疏松活性。在筛选碱性磷酸酶活性的所有化合物中,3 种化合物 4e、4j 和 4k 在成骨细胞分化刺激中以皮摩尔浓度显示出很强的活性。此外,通过茜素红 S 染色测定,这些化合物在矿化中也很有效。通过一系列其他体外实验再次验证了这些化合物。此外,分子动力学模拟表明,苯并呋喃和吡喃部分都需要适合 BMP-2 受体的活性部位,BMP-2 受体是成骨剂的关键靶点。获得的结果强烈表明,化合物 4e 是合成系列中具有潜在骨合成作用的物质,可进一步探索作为治疗骨质疏松症的药物先导物。